Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study

Journal of Clinical Oncology

Volumn 31, Issue 28, 2013, Pages 3517-3524

  Johnson, Philip J ^a   Qin, Shukui ^b   Park, Joong Won ^g   Poon, Ronnie T P ^f   Raoul, Jean Luc ^l   Philip, Philip A ^o   Hsu, Chih Hung ^q   Hu, Tsung Hui ^s   Heo, Jeong ^h   Xu, Jianming ^c   Lu, Ligong ^d   Chao, Yee ^r   Boucher, Eveline ^m   Han, Kwang Hyub ⁱ   Paik, Seung Woon ^j   Robles Aviña, Jorge ^u   Kudo, Masatoshi ^v   Yan, Lunan ^e   Sobhonslidsuk, Abhasnee ^w   Komov, Dmitry ^x   Decaens, Thomas ⁿ   Tak, Won Young ^k   Jeng, Long Bin ^t   Liu, David ^p   Ezzeddine, Rana ^p   Walters, Ian ^p   Cheng, Ann Lii ^q   more..

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b Nanjing Bayi Hospital   (China)

^c Beijing 307 Hospital   (China)

^d GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^e SICHUAN UNIVERSITY   (China)

^f UNIVERSITY OF HONG KONG   (Hong Kong)

^g National Cancer Center   (South Korea)

^h Pusan National University School of Medicine   (South Korea)

ⁱ Yonsei University College of Medicine   (South Korea)

^j Sungkyunkwan University School of Medicine   (South Korea)

^k Kyungpook National University Hospital   (South Korea)

^l INSTITUT PAOLI CALMETTES   (France)

^m Eugène Marquis Hospital   (France)

ⁿ HENRI MONDOR HOSPITAL   (France)

^o KARMANOS CANCER INSTITUTE   (United States)

^p BRISTOL MYERS SQUIBB   (United States)

^q NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^r TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^s CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^t CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^u High Specialty Regional Hospital   (Mexico)

^v KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^w MAHIDOL UNIVERSITY   (Thailand)

^x N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BRIVANIB; SORAFENIB; ALANINE; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; TRIAZINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPHONIA; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HEADACHE; HEPATITIS B; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPONATREMIA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN MANIFESTATION; TREATMENT DURATION; VOMITING; AGED; ANALOGS AND DERIVATIVES; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALANINE; CARCINOMA, HEPATOCELLULAR; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; PROTEIN KINASE INHIBITORS; SURVIVAL RATE; TRIAZINES; YOUNG ADULT;

EID: 84890274647     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.48.4410     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
2. Cao H, Phan H, Yang LX: Improved chemotherapy for hepatocellular carcinoma. Anticancer Res 32:1379-1386, 2012
3. European Association for the Study of the Liver-European Organisation for Research and Treatment of Cancer: EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 56:908-943, 2012
4. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
5. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34, 2009
6. Presta M, Dell'Era P, Mitola S, et al: Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 16:159-178, 2005
7. Grose R, Dickson C: Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 16:179-186, 2005
8. Mise M, Arii S, Higashituji H, et al: Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 23:455-464, 1996
9. Ogasawara S, Yano H, Iemura A, et al: Expressions of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines. Hepatology 24: 198-205, 1996
10. El-Assal ON, Yamanoi A, Ono T, et al: The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin Cancer Res 7:1299-1305, 2001
11. Uematsu S, Higashi T, Nouso K, et al: Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 20:583-588, 2005
12. Poon RT, Ng IO, Lau C, et al: Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 182:298-304, 2001
13. Casanovas O, Hicklin DJ, Bergers G, et al: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:299-309, 2005
14. Bergers G, Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592-603, 2008
15. Paez-Ribes M, Allen E, Hudock J, et al: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231, 2009
16. Ebos JM, Lee CR, Cruz-Munoz W, et al: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239, 2009
17. Wang L, Park H, Chhim S, et al: A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts. Mol Cancer Ther 11:864-872, 2012
18. Cai ZW, Zhang Y, Borzilleri RM, et al: Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol- 5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4] triazin-6- yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS- 540215). J Med Chem 51:1976-1980, 2008
19. Huynh H, Ngo VC, Fargnoli J, et al: Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 14:6146-6153, 2008
20. Bhide RS, Lombardo LJ, Hunt JT, et al: The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol Cancer Ther 9:369-378, 2010
21. Allen E, Walters IB, Hanahan D: Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res 17:5299-5310, 2011
22. Tovar V, Cornella, Villanueva A: FGF signaling is involved in acquired resistance to sorafenib in an in vivo model of hepatocellular carcinoma. Presented at the International Liver Cancer Association Conference, Hong Kong, China, September 2-4, 2011 (abstr 0-006)
23. Park JW, Finn RS, Kim JS, et al: Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 17:1973-1983, 2011
24. Finn RS, Kang YK, Mulcahy M, et al: Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 18:2090-2098, 2012
25. Llovet JM, Decaens T, Raoul J-L, et al: Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: Results from the randomized phase III BRISK-PS study. J Clin Oncol 31:3509-3516, 2013
26. Edeline J, Boucher E, Rolland Y, et al: Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 118:147-156, 2012
27. Lencioni R, Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52-60, 2010
28. Clopper CJ, Pearson ES: The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404-413, 1934
29. Garrett CR, Siu LL, El-Khoueiry A, et al: Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. Br J Cancer 105:44-52, 2011
30. Kaye SB, Siu LL, Jassem J, et al: Brivanib (B) in advanced ovarian cancer (OC): Subset results of a phase 2 randomized discontinuation trial (RDT). Ann Oncol 23:ix319, 2012 (suppl 9; abstr 9660)
31. Ratain MJ, Schwartz GK, Oza AM, et al: Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT). J Clin Oncol 29:213s, 2011(suppl; abstr 3079)
32. Schwartz GK, Maki RG, Ratain MJ, et al: Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial. J Clin Oncol 29:605s, 2011 (suppl; abstr 10000)
33. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139-144, 1998
34. Cheng A, Kang Y, Lin D, et al: Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 29: 256s, 2011 (suppl; abstr 4000)
35. MaverickNY: Pharma Strategy Blog: Why does sorafenib work in HCC but sunitinib does not? http:// pharmastrategyblog.com/2011/01/why-does-sorafenibwork- in-hcc-but-sunitinib-does-not.html/. (weblog) Accessed on November 29, 2012